Pulmonary hypertension

Board exam relevance: in 2 of more than 100 exam reports · rank 142
Synonyms
high blood pressure in the lungs, PH, pulmonary arterial hypertension, PAH, CTEPH
Specialty
Internal medicine · Cardiology
Images
X-ray 2
Last updated
10/2026 · Dr. Pascal Bafteh
Contents
  1. Images (2)
  2. Definition
  3. Classification
  4. Aetiopathogenesis
  5. Clinical features
  6. Diagnosis
  7. Treatment principles
  8. Keep learning in the app
  9. Further reading (open access)
  10. Cross-references

Images (2)

Pulmonary hypertension – X-ray: Chest X-ray PA and lateral with prominent central pulmonary arteries, together with CT showing a markedly dilated pulmonary trunk (wider than the aorta)X-ray
Chest X-ray PA and lateral with prominent central pulmonary arteries, together with CT showing a markedly dilated pulmonary trunk (wider than the aorta)Image: Hellerhoff (Wikimedia Commons) · CC BY-SA 4.0 · Source
Pulmonary hypertension – Chest X-ray PA: markedly dilated central pulmonary arteries on both sides with an abrupt change in calibre towards the periphery, enlarged heartX-ray
Chest X-ray PA: markedly dilated central pulmonary arteries on both sides with an abrupt change in calibre towards the periphery, enlarged heartImage: Hellerhoff (Wikimedia Commons) · CC BY-SA 4.0 · Source
1 / 2

Definition

Pulmonary hypertension (PH) is increased pressure in the pulmonary circulation. The pulmonary vessels may be constricted, pruned, lost or obstructed; severe PH leads to right ventricular overload and failure.

Hemodynamic definition

  • Pulmonary hypertension: mean pulmonary arterial pressure (mPAP) above 20 mmHg at rest; the previous threshold was 25 mmHg or more.
  • Precapillary PH: mPAP above 20 mmHg, pulmonary artery wedge pressure (PAWP) up to 15 mmHg and pulmonary vascular resistance (PVR) above 2 Wood units.
  • Isolated postcapillary PH: mPAP above 20 mmHg, PAWP above 15 mmHg, PVR up to 2 Wood units, e.g. in left heart disease.
  • Combined pre- and postcapillary PH: mPAP above 20 mmHg, PAWP above 15 mmHg and PVR above 2 Wood units.

Classification

Clinical classification (5 groups)

  • Group 1 – pulmonary arterial hypertension (PAH): idiopathic, heritable (e.g. BMPR2), drug- and toxin-induced, associated with congenital heart disease, connective tissue diseases, HIV infection, portal hypertension or schistosomiasis; pulmonary veno-occlusive disease; persistent pulmonary hypertension of the newborn.
  • Group 2 – PH due to left heart disease: diastolic dysfunction including heart failure with preserved ejection fraction, systolic dysfunction, valvular heart disease, inflow or outflow tract obstruction.
  • Group 3 – PH due to lung disease and/or hypoxia: COPD, interstitial lung disease, sleep-disordered breathing, chronic exposure to high altitude.
  • Group 4 – PH due to pulmonary artery obstruction: chronic thromboembolic pulmonary hypertension (CTEPH), non-thrombotic emboli (e.g. tumor, parasites).
  • Group 5 – unclear or multifactorial mechanisms: hematological disorders (chronic hemolytic anemia, sickle cell disease, myeloproliferative disorders, splenectomy), sarcoidosis, metabolic disorders, chronic kidney disease, fibrosing mediastinitis.

Aetiopathogenesis

  • Most common causes overall: left heart failure including diastolic dysfunction and parenchymal lung disease with hypoxia; others are sleep apnea, systemic rheumatic diseases and recurrent pulmonary embolism.
  • Genetics: mutations in the BMPR2 gene cause about 75 % of heritable PAH (autosomal dominant with incomplete penetrance); other genes (e.g. ALK-1, CAV1, ENG, KCNK3, SMAD9, TBX4) are much less common.
  • Triggering substances: certain appetite suppressants, amphetamines and methamphetamines and individual protein-kinase-blocking cancer drugs are definitely associated with PAH.
  • Increased pulmonary vascular resistance: vasoconstriction (enhanced activity of thromboxane and endothelin-1, reduced activity of prostacyclin and nitric oxide), proliferation of endothelium and smooth muscle, inflammation and remodelling of the vessel wall, local activation of coagulation.
  • Increased pulmonary venous pressure: in disorders of the left heart, most commonly heart failure with preserved ejection fraction.
  • Increased pulmonary blood flow: in congenital shunt lesions such as atrial and ventricular septal defects or patent ductus arteriosus.
  • Consequences: right ventricular hypertrophy, later dilatation and right heart failure with limited cardiac output on exertion.

Clinical features

  • Progressive exertional dyspnea and easy fatigability in almost all patients.
  • Atypical chest discomfort and light-headedness or presyncope on exertion indicate more severe disease.
  • Signs of right heart failure in advanced disease: right ventricular heave, widely split second heart sound with an accentuated pulmonary component, pulmonary ejection click, right ventricular third heart sound, tricuspid regurgitation murmur, jugular venous distension.
  • Liver congestion and peripheral edema as common late signs; lung auscultation is usually normal.

Diagnosis

  • Chest X-ray: enlarged hilar vessels that rapidly prune into the periphery, right ventricle filling the anterior airspace on the lateral view.
  • ECG: right axis deviation, R greater than S in V1, S1Q3T3 pattern (right ventricular hypertrophy), peaked P waves in II (right atrial dilatation).
  • Transthoracic Doppler echocardiography: right ventricular function and systolic pulmonary artery pressure; detection of causative left heart disease.
  • Search for the cause: pulmonary function tests with diffusing capacity, V/Q scintigraphy or CT angiography (thromboembolic disease), high-resolution CT, autoantibodies, polysomnography, HIV testing, liver tests, blood count.
  • Right heart catheterisation: confirms the diagnosis and severity; a mean pulmonary arterial pressure above 20 mmHg, a pulmonary artery wedge pressure up to 15 mmHg and a pulmonary vascular resistance above 2 Wood units characterise PAH; right-sided oxygen saturations to exclude a left-to-right shunt.
  • Severity: 6-minute walk distance and NT-proBNP or BNP; signs of right ventricular systolic dysfunction on echocardiography.
  • Family history and genetic testing (e.g. BMPR2) in heritable or idiopathic PAH.

Treatment principles

  • Treatment depends on the clinical group: in left heart and lung disease, treatment of the underlying condition comes first, and specific vasodilators are used there only exceptionally, for example an inhaled prostanoid in interstitial lung disease.
  • In pulmonary arterial hypertension, endothelin receptor antagonists, PDE-5 inhibitors, guanylate cyclase stimulators and prostanoids are used in a risk-adapted way, often in combination.
  • In chronic thromboembolic disease, pulmonary endarterectomy is the treatment of choice, otherwise balloon angioplasty or medical therapy; diuretics, oxygen and anticoagulation are added as appropriate.

Specific treatment regimens with drugs and doses are covered in the InnereFuchs app.

Keep learning in the app

In the InnereFuchs app you can learn Pulmonary hypertension with flashcards, exam questions and image tasks (ECG, chest X-ray, ultrasound, lab values) – free, in your browser or as an app.

Open in browser  About InnereFuchs →

Further reading (open access)

  1. MSD Manual Professional: Pulmonary Hypertension
  2. StatPearls: Pulmonary Hypertension
  3. Updated Clinical Classification and Hemodynamic Definitions of Pulmonary Hypertension and Its Clinical Implications

Cross-references

Keep learning

Keep learning with flashcards, exam questions and spot diagnoses in the InnereFuchs app – free, in your browser or as an app.

Related pages: Acute coronary syndrome (heart attack, STEMI/NSTEMI) · Heart failure · Atrial fibrillation

Note: Learning content for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.